Facebook link Linked In link You Tube link

FOCIS 2013 Header

AboutProgram at a GlanceAbstractsVisit SeaportSupport/Exhibit

Download the FOCIS 2013 Scientific Program (PDF)

View the FOCIS 2013 Mobile App

Click here for instructions on adding the FOCIS Mobile App to your homescreen.

Scientific Program

Since its conception in 2001, the FOCIS organization has grown to 53 Member Societies that collectively represent more than 65,000 basic and clinician scientists. Each year, the FOCIS meeting brings together researchers and clinicians from around the world, working in more than 30 clinical specialties and provides them with a forum to gather and share the latest finding, breakthroughs and therapies related to human disease. The FOCIS concept posits that interrelationships between fields sharing clinical immunology expertise will build a better and faster pathway to improve knowledge that leads to new therapies for inflammatory diseases

World-renowned speakers in the field of clinical immunology will explore their work and touch on the five themes embraced by FOCIS: Immunoregulation, Immunogenetics, Host Defense, Immunodiagnosis, Immunotherapy.

Interactive Program Feature

2013 Scientific Program

Wednesday, June 26th, 2013

8:00 am - 5:00 pm
FOCISed Course

Basic Immunology in Medicine: Update 2013 (separate registration required)

Thursday, June 27th, 2013

8:00 am - 5:00 pm
FOCISed Course

Interventional Immunology (separate registration required)

8:00 am - Noon
Member Society Symposia (included in FOCIS 2013 registration rate)

Nanoparticle Vaccine Delivery Systems for Type 1 Diabetes 
Programmed by JDRF

New Technologies in Transplantation Immunology
Co-programmed by the Transplantation Society (TTS) and the American Society for Histocompatibility & Immunogenetics (ASHI)

Cord Blood Derived Cellular Therapies
Programmed by the American Society for Blood and Marrow Transplantation (ASBMT)

12:45 pm - 4:45pm

Tissue-Intrinsic Mechanisms of Immunoregulation
Co-programmed by Americas Committee for the Treatment and Research of Multiple Sclerosis (ACTRIMS) and the CHIR Human Immunology Network (CHIN)

Assessment of Abnormalities in the Human Innate Immune System
Co-programmed by the Association of Medical Laboratory Immunologists (AMLI), American Society of Histocompatability and Immunogenetics (ASHI), and the Academy of Clinical Laboratory Physician Scientists (ACLPS)

A New Look at Allergen Immunotherapy  
Co-programmed by the National Institute of Allergy and Infectious Diseases (NIAID) and the American Academy of Allergy, Asthma & Immunology (AAAAI)

Recent Advances in Systemic Autoimmune Diseases: Focus on Lupus
Co-programed by the Alliance for Lupus Research (ALR), Lupus Foundation of America (LFA), and the Lupus Research Institute (LRI)

5:30 pm - 6:30 pm
Opening Keynote Address

T Cell Control of HIVBruce Walker, MD, Ragon Institute of MGH, MIT, and Harvard
Chair: David Hafler, MD, Yale University
-Discuss the role of CD8 T cells in immune control; Discuss the effect of clonotype on TCR-peptide-MHC interaction; Describe the role of CD4 T cells in adaptive immunity to HIV.

This email address is being protected from spambots. You need JavaScript enabled to view it.

6:30 pm - 8:30 pm

Opening Reception

Friday, June 28th, 2013

8:00 am - 9:45 am
Plenary Session: Targeting Signalling Pathways in Inflammatory Disease
Chair: Andrew Lichtman, MD, PhD, Brigham and Women's Hospital

Back to the Future: Jakinibs and Oral Targeted Therapy, John O'Shea, MD, National Institutes of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health
-Discuss the current status of Jak inhibitors, describe their mechanism of action, extroplate the future for this class of immunodulatory agents.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Regulating Tyrosine Phosphorylation by Antigen Receptors, Arthur Weiss, MD, PhD, University of California, San Francisco
-Describe how antigen receptor signaling is initiated and controlled; Illustrate how intervening at certain points in antigen receptor pathways can block certain functions; Report on therapies in development or in clinical trials that target tyrosine kinases in antigen receptor pathways.

This email address is being protected from spambots. You need JavaScript enabled to view it.

P13K's in Immunity and Inflammation, Klaus Okkenhaug, PhD, The Babraham Institute
-Explain the P13K signaling pathway and pre-clinical progress in the development of P13K to treat autoimmune and inflammatory disease.

This email address is being protected from spambots. You need JavaScript enabled to view it.

10:00 am - 11:45 am
Plenary Session: Removing the Brakes on Anti-Tumor Immune Responses
Chair: Daniel Rotrosen, MD, National Institute of Allergy and Infectious Disease

T Cell Function in the Tumor Micro- and Macro-environments, Daniel Speiser, MD, Ludwig Center for Cancer Research Lausanne
-Describe the role of T cells in cancer; Describe immune suppressive mechanisms in cancer; Discuss current challenges in R&D for optimizing cancer immunotherapy.

This email address is being protected from spambots. You need JavaScript enabled to view it.

PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer, Suzanne Topalian, MD, Johns Hopkins University
-Distinguish the mechanism of action and treatment outcomes of the PD-1 blockade in cancer. 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Mechanisms of Protective Tumor Immunity, Glenn Dranoff, MD, Dana-Farber Cancer Institute

This email address is being protected from spambots. You need JavaScript enabled to view it.

1:15 pm - 3:00 pm
Concurrent Thematic Symposium: Innate Lymphoid Cells in Human Disease
Chair: Shannon Turley, PhD, Dana Farber Cancer Institute

New Insights in Development and Function of Human Innate Lymphoid Cells, Hergen Spits, PhD, University of Amsterdam
-Identify various subsets of ILC; Discuss development and function of human ILC1 and ILC2; Discuss the possible role of ILC disease.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: A B6/Castaneus Congenic Mouse Strain Harboring High Number of GFP Tagged Polyclonal MAIT Cells, Olivier Lantz, MD, PhD, Institut Curie

This email address is being protected from spambots. You need JavaScript enabled to view it.

Innate Lymphoid Cells in Mucosal Immunity,  Marco Colonna, PhD, Washington University
-Explain the concept of innate lymphoid cells (ILC) in immune responses; Examine the potential impact of ILC in human diseases, particularly inflammatory bowel disease

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: Control of IL-17A Induction in Coltiogenic Innate Lymphoid Cells, Joerg Ermann, MD, Brigham and Women's Hospital

This email address is being protected from spambots. You need JavaScript enabled to view it.

Immune Regulation at Barrier Surfaces, David Artis, PhD, University of Pennsylvania
-Discuss the immune pathways that regulate responses to infections, injury and inflammation at the body's barrier surfaces including the skin, lung and intestine.

This email address is being protected from spambots. You need JavaScript enabled to view it.
Concurrent Thematic Symposium: From Genes to Mechanisms
Chair: Paul Anderson, MD, PhD, Harvard Medical School and Brigham and Women's Hospital

From GWAS to Biology, David Hafler, MD, Yale University
-Discuss the results of GWAS; Explain the tools that can be used to go from GWAS to biologic function.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: The SLE-Associated TLR7 Variant Confers Differential Gene Expression Modulated by MicroRNAs, Yun Deng, MD, University of California, Los Angeles

This email address is being protected from spambots. You need JavaScript enabled to view it.

Genomics and Patient Stratifiction in Autoimmunity: The End of the Beginning? Ken Smith, PhD, University of Cambridge
-Describe how focused analysis of GWAS can define clinically relevant patient subgroups; Employ the use of transcriptomics to predict long-term outcome in immune-mediated disease.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: Admixture Mapping in Lupus Identifies Three Functional Variants Within IFIH1 Associated with Apoptosis and Inflammation, Swapan Nath, PhD, Oklahoma Medical Research Center

This email address is being protected from spambots. You need JavaScript enabled to view it.

Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis, Anne Bowcock, PhD, Washington University
-Associate over 30 common gene variants known to predispose to psoriasis; Explain the rare and common variants in CARD14 that lead to psoriasis and psoriatic arthritis; Describe how pathways altered in psoriasis suscepitibility through genetic variation include those leading to NF-kB activation, T cell regulation, innate host defense and macrophage activation.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Concurrent Thematic Symposium: B Cells in Immune Inflammation
Chair: Shiv Pillai, MD, PhD, Harvard

 Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance, Eric Meffre, PhD, Yale University

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: A Novel GM-CSF+TNFαhighIL-6highIL-10-Human B Cell Subset is Abnormally Increased in Patients with Multiple Sclerosis, Rui Li, MD, McGill University, Montreal Neurological Institute

This email address is being protected from spambots. You need JavaScript enabled to view it.

B Cells in Human Diseases, Andrew Chan, MD, PhD, Genentech, Inc.
-Contrast diseases in which B cell depletion has demonstrated efficacy and lack of efficacy; Explain the breadth of mechanisms by which B cells may contribute to human diseases.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: Alpha(v) Integrins Engage Autophagy Machinery to Modulate Specific B Cell Immune Responses, Mridu Acharya, Massachusetts General Hospital/ Harvard Medical School

This email address is being protected from spambots. You need JavaScript enabled to view it.

How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis, Joan Goverman, PhD, University of Washington
-Discuss B cell function as antigen-presenting cells during pre-clinical EAE; Explain that B cells faciltate the induction of inflammatory mediators in the central nervous system; Relate that B cells differentially influence reactivation of Th1 and Th17 cells.

This email address is being protected from spambots. You need JavaScript enabled to view it.

3:15 pm - 5:15 pm

Featured Course: Principles of Flow Cytometry for Immune Monitoring Part I
-Discuss the factors that contribute to variability in multicenter flow cytometry studies; Identify the steps that have been taken by different groups to control these factors; Cite the successes of the various consortia that have undertaken flow cytometry standardization, and what gaps still remain.

 EuroFlow Consortium, Jacques Van Dongen, MD, PhD, Erasmus MC

This email address is being protected from spambots. You need JavaScript enabled to view it.

 Cancer Immunotherapy Immunoguiding Program, Cedrick Britten, PhD, TRON

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cancer Immunotherapy Consortium, Sylvia Janetzki, MD, ZellNet Consulting, Inc. 

This email address is being protected from spambots. You need JavaScript enabled to view it.

 EQAPOL (NIAID), Tom Denny, MSc, M.Phil, Duke Human Vaccine Institute and Center for HIV/AIDS Vaccine

This email address is being protected from spambots. You need JavaScript enabled to view it.

FOCIS Human ImmunoPhenotyping Corsortium, Holden Maecker, PhD, Stanford University and J. Philip McCoy, PhD, National Heart Lung and Blood Institute

This email address is being protected from spambots. You need JavaScript enabled to view it.

3:15 pm - 5:15 pm

Concurrent Oral Abstract Sessions

Keeping the Stats: Immune Monitoring
Chair: William Robinson, MD, PhD, Stanford University

OR.1 Local and Systemic Immune Responses Predict Clinical Outcomes in Influenza Virus Infection Independently of Age and Viral Titer, Christine Oshansky, PhD, St. Jude's Children's Research Hospital

OR.2 Quantification of IgM and IgA Anti-pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency, Cinzia Milito, MD, PhD, Sapienza University of Rome

OR.3 Exploring Necrotizing Autoimmune Myopathies with a New Quantitative Anti-HMGCR Assay: Correlation with CK Levels, Olivier Boyer, MD, PhD, University of Rome

OR.4 Interferon and TNF Family Soluble Inflammatory Mediators are Detected Prior to and Increase at Systemic Lupus Erythematosus Classification, Judith James, MD, PhD, Oklahoma Medical Research Center

OR.5 Do Tc17 Cells Contribute to the Inflammatory Joint Environment in Psoriatic Arthritis?, Bina Menon, MRCP, King's College London

OR.6 Decreased TCR Diversity in Patients of Common Varable Immunodeficiency, Manish Ramesh, MD, PhD, Icahn School of Medicine- Mount Sinai

OR.7 Signaling Pathway Proteomic Signatures as Biomarkers for Autoimmunity, Richard James, PhD, Seattle Children's Research Institute

OR.8 Features of DRB1*01:01-Restricted FVIII2194-2213 T-Cells that are Associated with FVIII Neutralizing Antibodies and Responses to Immune Tolerance Induction in Hemophilia A, Ruth Ettinger, PhD, Puget Sound Blood Center

Designated Hitters: Immune Effectors
Chair: Francisco Quintana, PhD, Brigham and Women's Hospital

OR.9 IL-27p28 Inhibits CNS Autoimmunity by Concurrently Antagonizing Th1 and Th17 Responses, Rachel Caspi, PhD, National Eye Institute, National Institutes of Health 

OR.10 Transactivation of Socs3 by PPARγ Prevents Th17-related Cancer Growth, Helene Berger, Inserm U866

OR.11 Selective ROCK2 Inhibitor Down-regulates IL-17 and IL-21 Secretion in Human T Cells, Alexandra Zanin-Zhorov, PhD, Kadmon Research Institute

OR.12 Enhanced Production of IL-17A in Severe Asthma is Inhibited by 1alpha,25-dihydroxyvitamin D3 in a Glucocorticoid-independent Fashion: A Role for CD39?, Emma Chambers, PhD, King's College London

OR.13 Genetic Inhibition of MST1 Blocks Lymphocyte Function and Protects Against Autoimmunity, Konstantin Salojin, MD, PhD, Lexicon Pharmaceuticals, Inc.

OR.14 Toll-like Receptor-mediated IRE1a Activation as a Therapeutic Target for Inflammatory Arthritis, Deyu Fang, MD, PhD, Northwestern University

OR.15 Alloantibody and Complement Activate Non-Canonical NF-kB Signaling in Graft Endothelial Cells and Promote T Cell-Mediated Cardiac Allograft Vasculopathy, Dan Jane-wit, MD, PhD, Yale University

OR.16 Post-translational Modifications Increase Immune Recognition of Beta Cell Antigens in Type 1 Diabetes, Eddie James, PhD, Benaroya Research Institute

Moneyball: Genetic Control of the Immune Response
Chair: Elaine Reed, PhD, University of California, Los Angeles

OR.18 Genetic Variation Near IRF8 is Associated with Serologic and Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis, Timothy Niewold, MD, University of Chicago

OR.19 Genetic Variants Associated with Multiple Sclerosis Result in Enhanced NFkB Signaling and Responses to Inflammatory Cytokines, William Housley, PhD, Yale University

OR.21 A Dominantly Inherited Mutation in TWEAK is Associated with Antibody Defiency, Ashish Jain, MD, National Insitutes of Health

OR.22 Genetically-determined Cytokine Programs of Human NK Cells Uncover a Novel Mechanism of NK cells and Killer Cell IgG-like Receptor (KIR) Genes in Crohn’s Disease (CD) Susceptibility, Lin Lin, MD, University of California, Los Angeles

OR.23 Killer Immunoglobulin-like Receptor (KIR)-B/x Centromeric Linkage Group Influences the Development of Post-transplant Lymphoproliferative Disorder (PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT), Rehan Faridi, PhD, University of Calgary 

5:30 pm - 6:30 pm
Keynote Address

Immune Regulation by mRNA and Protein Degradation, Shizuo Akira, MD, PhD, Osaka University
Chair: C. Garrison Fathman, MD, Stanford University
-Describe the importance of MRNA decay in the immune and inflammatory reaction; Describe negative regulation of immune response by the novel Rnase; Restate the role of Rnase in T cell activation.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Saturday, June 29th, 2013

8:00 am - 9:45 am
Plenary Session: Measuring Antigen Specific Responses
Chair: Steven Ziegler, PhD, Benaroya Research Institute

Biomarkers & Beyond, Jerry Nepom, MD, PhD, Benaroya Research Institute
-Apply approaches for detection of rare cells involved in human immune disease pathogenesis; Employ strategies for characterizing functional and clinical correlates of antigen-specific cells in human subjects during immune intervention therapy.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Diseases, Mark Davis, PhD, Stanford University
-Restate that with improvements in peptide-MHC tetramer technology, we can now directly characterize specific T cells prior to any infection or stimulation in the pre-immune repertoire; Contrast that in adults, but not newborns, there is an abundance of memory phenotype T cells in unexposed individuals, which may explain the susceptiblity of young children to infectious diseases; Extrapolate why thymic deletion cannot be a major mechanism of peripheral tolerance; State that the principal concern of the T cell repertoire is to combat infectious diseases.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The Use of the Immune Epitope Database (IEDB) to Study Autoimmune Epitope Data, Alessandro Sette, PhD, La Jolla Institute for Allergy and Immunology
-Report how the Immune Epitope Database and Analysis Resource (IEDB), originally developed to focus on infectious disease data, can be used to analyze epitope data related to autoimmunity; Examine how common questions related to diabetes epitopes can be answered using the IEDB and the results of the queries.

This email address is being protected from spambots. You need JavaScript enabled to view it.

10:00 am - 11:45 am
Plenary Session: Mechanistic Basis for Targeted Therapies
Chair: Frank Nestle, MD, King's College London

Novel Regulatory Pathways in Rheumatoid Arthritis-Towards New Therapeutics? Iain McInnes, MD, PhD, University of Glasgow
-Describe novel regulatory pathways that promote the pathogenesis of rheumatoid arthritis; Interpret how these fit in the context of current treatment of rheumatoid arthritis.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Pathogenic Cytokine Circuits in Psoriasis, James Krueger, MD, PhD, The Rockefeller University
-Distinguish the diversity of dendritic cell and T cell subsets in active skin lesions; Contrast the different effector pathways and cytokine effects of Th1 vs. Th17 T cell subsets on epidermal keratinocytes; Discuss emerging data that suggests the central pathogenic pathway psoriasis is IL-23 regulated Th17 (IL-17) driven and that there is a strong interaction of this pathway with TNF.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE, Virginia Pascual, MD, Baylor Institute for Immunology Research

This email address is being protected from spambots. You need JavaScript enabled to view it.

1:15 pm - 3:00 pm
Concurrent Thematic Symposium: Nucleic Sensing and Immune Responses
Chair: Virginia Pascual, MD, Baylor Institute for Immunology Research

Cell-intrinsic Detection of Viral Nucleic Acids, Caetano Reis e Sousa, DPhil, London Research Institute
-Explain cell-intrinsic mechanisms of antiviral resistance and how they can, when dysregulated, contribute to autoimmune disease.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: NOD-Like Receptor NLRP10 Regulates Migration of Dendritic Cells and Dictates Adaptive Helper T Cell, Stephanie Eisenbarth, MD, PhD, Yale University

This email address is being protected from spambots. You need JavaScript enabled to view it.

Endogenous Retroelements and Autoimmunity, Daniel Stetson, PhD, University of Washington
-Restate that innate immune sensors that detect foreign DNA are important for defense against DNA viruses, invasive bacteria, and infectious retroviruses; Describe recent work that has found that the endogenous retroelements that comprise 40% of the human genome can also generate reverse-transcribed cDNAs that are detected by these same sensors, leading to autoimmune disease; Describe the intersection between retroelement biology and innate immunity, with emphasis on how metabolism of endogenous reverse transcription products prevents autoimmune disease.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: Cholinergic Neuronal Signals Attenuate Inflammasome Activation Through Inhibiting Mitochondrial Stress, Ben Lu, MD, Feinstein Institute for Medical Research

This email address is being protected from spambots. You need JavaScript enabled to view it.

The Innate Immune Response to Malaria is Due to the Recognition of DNA, Douglas Golenbock, MD, University of Massachusetts Medical School
Session Comment/Question

Concurrent Thematic Symposium: T Cell Memory vs. Exhaustion
Chair: Mark Anderson, MD, PhD, University of California, San Francisco

CD8 T Cell Exhaustion vs. Tolerance: The Transition from a Cell-extrinsic Fate, Phil Greenberg, MD, University of Washington
-Describe the cellular and molecular differences between an exhausted and a tolerant state; Explain the epigenetic regulation that maintains CD8 T cells in a tolerant state; Identify strategies to overcome or maintain tolerance.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: The Transcription Factor BATF Controls CD8+ T Cell Effector Differentiation, R. Anthony Barnitz, PhD, Dana-Farber Cancer Institute, Harvard Medical School

This email address is being protected from spambots. You need JavaScript enabled to view it.

Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death, Nick Restifo, MD, National Cancer Institute

-Cite that T cells are capable of 'sterilizing' and curing widely metastatic cancer; Explore the molecular and metabolic control of T cell differentiation, senescence and death; Discuss how adoptive cell transfer (ACT) enables the selection and 'programming' of stem cell-like anti-tumor T cells.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: Clinical Significance and Therapeutic Potential of the Programmed Death Ligand-1 and Programmed Death Ligand-2 Expression in Human Colorectal Cancer, Martin Gasser, MD, University of Wuerzburg

This email address is being protected from spambots. You need JavaScript enabled to view it.

T Cell Memory and Exhaustion, Andrew Adams, MD, PhD, Emory University
-Identify the distinguishing features of memory, exhausted and senescent T cells; Describe the functional consequences of these distinct phenotypes; Restate therapeutic implications of memory dominant versus exhaustion dominant T cell repertoires. 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Concurrent Thematic Symposium: Microbiome and Immune Development
Chair: Scott Snapper, MD, PhD, Children's Hospital Boston, Brigham and Women's Hospital and Harvard Medical School

The Gut Microbiome and Regulation in CNS Demyelinating Disease, Lloyd Kasper, MD, Dartmouth College
-Discuss the gut microbiome and its role in autoimmunity, in particular central nervous system demyelination.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: Colonic DCs But Not Small Intestintal DCs Instruct CD8+ T Cells To Home to the Colon, Alison Hogg, MD,  Center for Cancer Research, National Cancer Institute, National Institutes of Health

This email address is being protected from spambots. You need JavaScript enabled to view it.

Compartmentalized Control of Tissue Immunity by CommensalsYasimine Belkaid, PhD, National Institute of Allergy and Infectious Disease
-Discuss the role of commensals in the control of immunity to pathogens in the gut and the skin.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract Presentation: The Development of Spontaneous Autoimmunity to Neuroretina is Influenced by Intestinal Microbiota, Carlos Zárate-Bladés, MD, PhD  National Eye Institute, National Insitutes of Health

This email address is being protected from spambots. You need JavaScript enabled to view it.

Intestinal Microbiota in Immunity and Autoimmunity, Alexander Chervonsky, MD, PhD, University of Chicago
-Restate mechanisma that microbiota uses to control autoimmunity and inflammation.

This email address is being protected from spambots. You need JavaScript enabled to view it.

3:15 pm - 5:15 pm

Featured Course: Principles of Flow Cytometry for Immune Monitoring Part II
-Compare and contrast the applications best suited for imaging and mass cytometry; Discuss the current limitations of each of these technologies.

Imaging Cytometry, J. Philip McCoy, PhD, National Heart Lung and Blood Institute

This email address is being protected from spambots. You need JavaScript enabled to view it.

Mass Cytometry (CyTOF), Holden Maecker, PhD, Stanford University

This email address is being protected from spambots. You need JavaScript enabled to view it.

3:15 pm - 5:15 pm

Concurrent Oral Abstract Sessions

Performance Enhancers: Promoting Immune Responses
Chair: Terri Laufer, MD, University of Pennsylvania Medical School

OR.24 Inhibiting the Development of Immunosuppressive Gr-1+ Dendritic Cells in Tumors by Blocking TLR2 Enhances Immunotherapy, Michael Tang, University of Toronto

OR.25 Dendritic Cells Expressing Low Levels of IL-10 and CD14 Induce Immunological and Clinical Response in Prostate Carcinoma Patients, Luciano Castiello, PhD, National Institutes of Health

OR.26 Mucosal Adjuvant-mediated Viral Load Reduction During Acute and Chronic Stages of SIVmac251-infection in Indian Rhesus Macaques, Yongjun Sui, PhD, National Cancer Institute, National Institutes of Health

OR.27 Variable Cross-Presentation of HIV Epitopes by Dendritic Cells and Macrophages to CD8 T Cells Uncovers Differences in Intracellular Peptide Degradation Rates, Jens Dinter, Ragon Institute of MGH, MIT and Harvard

OR.28 Influenza Vaccination in Complete Remission Lymphoma Patients Treated with Rituximab-containing Chemotherapy: Data from Three Sequential Studies Assessing Three Different Vaccine Formulations, Davide Bedgonetti, MD, PhD, National Insitutes of Health

OR.29 Gene Signatures of Proliferating B Cells Predict Response to Influenza Vaccination, Yan Tan, Broad Institute of MIT, Harvard

OR.30 Rhinovirus Challenge Promotes Allergen Responsiveness in Basophils and Dendritic Cells from Atopic Asthmatics, Rachana Agrawal, PhD, University of Virginia

Umpires: Regulating Immune Responses
Chair: George Tsokos, MD, Beth Israel Deaconess Medical Center

OR.31 Temporally Defined Inflammatory Pathways Modulate Distinct Effector and Regulatory CD4 T Cell Responses, Lucas Thompson, PhD, Benaroya Research Institute

OR.32 Linking Regulatory T Cell Anomalies to IL-2 Deficiency in Patients with Systemic Lupus Erythematosus, Caroline von Spee, MSc, Charité, University Hospital

OR.33 Interferons Lambda, IL-28 and IL-29, are Increased in Chronic HCV Infection and Induce Myleoid Dendritic Cell-Dependent Expansion of FoxP3+ Regulatory T Cells, Angela Dolganiuc, University of Florida

OR.34 The Therapeutic Potential of Allogeneic CD8 Regulatory T Cells Generated ex vivo, Jing-Ni Ou, PhD, University of SouthernCalifornia, Keck School of Medicine

OR.35 Amelioration of Arthritis through Mobilization of Peptide-Specific CD8+ Regulatory T Cells, Jianmei Leavenworth, Dana Farber Cancer Institute, Harvard Medical School

OR.36 High Salt Blocks Suppressive Activity of Human Foxp3+ Regulatory T Cells, Markus Kleinewietfeld, PhD, Yale University

OR.37 Nanoparticle-induced Tolerance in Fully MHC-mismatched Allogeneic Islet Transplantation, Kelan Hlavaty, Northwestern University 

OR.38 Dendritic Cell Targeting Microparticle Vaccine for Type 1 Diabetes, Ben Keselowsky, PhD, University of Florida

Managers: Modulating the Immune Response
Chair: Jane Buckner, MD, Benaroya Research Institute

OR.39 IL-27 Enhances LPS-Induced Inflammasome Induction and IL-1β Production in Myeloid Cells, Katrina Gee, PhD, Queen's University

OR.40 Interleukin-7 is Produced by Afferent Lymphatic Vessels and Supports Lymphatic DrainageCornelia Halin, PhD, ETH Zurich

OR.41 IL-2 Production by CD8 T Cells Forecasts the Formation of Immunological Memory, Rakesh Bakshi, PhD, University of Alabama at Birmingham

OR.42 Longevity and Turnover of Human Naïve T Cells in Lymphoid Tissue, Joseph Thome, Columbia Center for Translational Immunology

OR.43 Paradoxical Reduction of AIRE Expression in the Thymus of Down Syndrome Individuals May Explain their Predisposition to Polyendocrine Autoimmunity, Ricardo Pujol Borrell, MD, PhD, Universitat Autonoma de Barcelona

OR.44 STAT3 Signaling Through gp130 is Critical for Human CD8+ T Cell Maturation into Cytotoxic T Lymphocytes, Takashi Yamazaki, PhD, Saitama Medical Center

OR.45 TIM-4 Expressed on Eosinohils from Lung and Gut-draining Lymph Nodes Cotimulates T Cell Expansion, Haibin Wang, MD, PhD,  Beth Israel Deaconess Medical Center, Harvard Medical School

5:30 pm - 6:30 pm
Presidential Keynote Address

Controlling Autoimmunity: The Effector/Regulatory T Cell Balance, Abul Abbas, MD, University of California, San Francisco 
Chair: Robert Nussenblatt, MD
-Differentiate between effectory and regulatory T cells and their roles in autoimmune diseases; Explain the roles of the cytokine IL-2 in immune responses and inflammatory diseases; Apply how these concepts develop new therapies.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 Sunday, June 30th, 2013

8:15 am - 5:15 pm
FOCISed Course

Clinical Trials for Immunologic Disease (separate registration required)

8:00 am - 9:45 am
Plenary Session: Systems Immunology and Disease
Chair: Vijay Kuchroo, PhD, Harvard Medical School and Brigham and Women's Hospital

Using Top-down Systems Approaches to Better Understand Immune Function in vivo, Ron Germain, MD, PhD, National Institutes of Health
-Explain the value of collecting large scale, multiplex data sets indeveloping a global picture of immune system state; Explain the critical role of computational analysis in generating value from such complex data sets; Interpret real world examples of how such systems methods have led to insights into the origins of pathogen-driven immunopathology and variations in vaccine responses.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Presentation TBA, Nir Hacohen, PhD, Harvard Medical School

This email address is being protected from spambots. You need JavaScript enabled to view it.

Analyzing Mechanisms of Gut Microbiome Disfunction in Inflammatory Disease, Curtis Huttenhower, PhD, Harvard
-Describe recent profiling of the large-scale diversity of the human microbiome and the analytical and experimental tools that have emerged to link microbial community structure with biomolecular details, metabolic function, and disease phenotypes, Discuss the application of bioinformatic methods for human microbiome profiling to inflammatory conditions including IBD and pouchitis, particularly focusing on the integration of 16S, metagenomic, and metatranscriptomic assays to identify specific disrupted microbial processes, Discuss the perturbation of redox metabolism in established Crohn's disease and ulcerative colitis, distinct functional disruptions during early-onset IBD, and substantial remaining variation explained by host-specific immune gene expression in adjacent epithelial tissue.

This email address is being protected from spambots. You need JavaScript enabled to view it.

10:00 am - 11:45 am
Plenary Session: The Link Between Metabolism and Inflammation
Chair: Andrew Luster, MD, PhD, Massachusetts General Hospital

Targeting Inflammation in Type 2 Diabetes and Cardiovascular Disease Steven Shoelson, MD, PhD, Harvard Medical School

This email address is being protected from spambots. You need JavaScript enabled to view it.

A New Model for T Cell Differentiation Based on Metabolism, Jonathan Powell, MD, PhD, Johns Hopkins University
-Explain how mTOR regulates CD4+ T cell differentiation; From a metabolic perspective, compare how are memory cells and T regs are similar.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Metabolic Control of T Cell Function and Fate, Ericka Pearce, PhD, Washington University
-Describe the interdependence between metabolic pathways and immune responses. 

This email address is being protected from spambots. You need JavaScript enabled to view it.



Share